SCHEMBL3485265

SCHEMBL3485265

Cc1cccc(C)c1NC(=O)CN1CCC(N(C(C)C)S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
LMNA P02545 3/20 0.47
HSD17B10 Q99714 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
MAPT P10636 2/20 0.46
CACNA1B Q00975 5/20 0.45
GAA P10253 2/20 0.44
UBE2M P61081 3/20 0.44
DCUN1D1 Q96GG9 3/20 0.44
TSHR P16473 1/20 0.44
DRD4 P21917 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
DRD3 P35462 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPK1 P28482 1/20 0.43
CACNA1C Q13936 1/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3486183 0.91 LMNA (0.48) ALDH1A1LMNAHSD17B10SMN1; SMN2MAPT
SCHEMBL3485824 0.89 ALDH1A1 (0.52) ALDH1A1LMNAHSD17B10SMN1; SMN2MAPT
SCHEMBL3485875 0.89 CACNA1B (0.58) CACNA1B
SCHEMBL13541695 0.89 ALDH1A1 (0.48) ALDH1A1LMNADRD4DRD3TP53
SCHEMBL3485705 0.88 ALDH1A1 (0.54) ALDH1A1LMNAHSD17B10SMN1; SMN2MAPT
SCHEMBL3485918 0.87 TSHR (0.56) ALDH1A1LMNAHSD17B10SMN1; SMN2MAPT
SCHEMBL3485688 0.86 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10SMN1; SMN2MAPT
SCHEMBL3485872 0.85 CACNA1B (0.47) ALDH1A1LMNAHSD17B10SMN1; SMN2MAPT
SCHEMBL3485489 0.85 L3MBTL1 (0.51) ALDH1A1LMNAHSD17B10SMN1; SMN2MAPT
SCHEMBL13002406 0.85 CACNA1B (0.51) LMNASMN1; SMN2CACNA1BGAAUBE2M

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US claimed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US claimed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO claimed
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US disclosed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels CACNA1A, CACNA1E, CACNA1B ALDH1A1 2210/4885LMNA 1608/4885HSD17B10 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.